The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of durvalumab re-treatment +/- prednisone in patients who discontinued prior checkpoint therapy due to immune related toxicity (CCTG IND.238A).
 
Peter Michael Ellis
Honoraria - AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada; Sanofi/Aventis
 
Sara Kristina Taylor
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; EMD Serono; Knight Therapeutics; Merck; Novartis; Novartis Canada Pharmaceuticals Inc; Pfizer/EMD Serono
 
Penelope Ann Bradbury
Consulting or Advisory Role - Mirati Therapeutics
(OPTIONAL) Uncompensated Relationships - Abbvie; Bristol-Myers Squibb
 
John R. Goffin
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Rosalyn A. Juergens
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck Sharp & Dohme; Mirati Therapeutics; Novartis Canada Pharmaceuticals Inc; Roche Canada; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Fusion Pharmaceuticals; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche Canada; Sanofi/Regeneron; Takeda
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Fusion Pharmaceuticals (Inst); Janssen (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
 
Scott A. Laurie
Honoraria - AstraZeneca; Boehringer Ingelheim; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Pfizer
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Jennifer L. Spratlin
Consulting or Advisory Role - Amgen; Astellas Pharma; Incyte; Taiho Oncology
Research Funding - AZ Canada (Inst)
 
Nicole Grace Chau
Honoraria - Bayer; Eisai; Ipsen; Lilly; Merck; Roche Canada
Consulting or Advisory Role - Bayer; Eisai; Lilly; Merck; Roche
Research Funding - GlaxoSmithKline; Merck (Inst); Pfizer (Inst)
 
Danielle Charpentier
Consulting or Advisory Role - Gilead Sciences; Novartis
Research Funding - Gilead Sciences (Inst); Merck (Inst); Roche (Inst)
 
Courtney Coschi
No Relationships to Disclose
 
Joana Sederias
No Relationships to Disclose
 
Siwei Zhang
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca (Inst); Bayer (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Repare Therapeutics (Inst)
 
Pierre-Olivier Gaudreau
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Novartis (Inst); Repare Therapeutics (Inst); Repare Therapeutics (Inst)